UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Acquires 2,774,933 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• UBS Asset Management has increased its stake in Arrowhead Pharmaceuticals by 138%, acquiring an additional 2,774,933 shares to hold a total of 4,785,062 shares worth approximately $60.96 million.
• Multiple institutional investors have shown interest in Arrowhead, with significant increases in holdings by firms like Goldman Sachs and ADAR1 Capital Management, indicating strong institutional backing for the stock.
• Analysts currently rate Arrowhead Pharmaceuticals with a consensus of "Buy" and a target price of $43.14, despite recent earnings missing expectations.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 138.0% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,785,062 shares of the biotechnology company's stock after purchasing an additional 2,774,933 shares during the quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned 3.46% of Arrowhead Pharmaceuticals worth $60,962,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in ARWR. GAMMA Investing LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at approximately $49,000. CWM LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 2,523 shares during the last quarter. KBC Group NV grew its holdings in shares of Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 2,132 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the 1st quarter valued at approximately $133,000. 62.61% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ARWR. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 2nd. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. B. Riley upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. Chardan Capital reiterated a "buy" rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Finally, Wall Street Zen downgraded shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $43.14.

Arrowhead Pharmaceuticals Stock Down 2.6%

Shares of Arrowhead Pharmaceuticals stock traded down $0.82 during trading on Friday, reaching $30.69. 4,937,943 shares of the company traded hands, compared to its average volume of 2,707,305. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $31.67. The company has a 50 day moving average price of $21.17 and a 200-day moving average price of $16.95. The firm has a market capitalization of $4.24 billion, a PE ratio of -23.98 and a beta of 1.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The company had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same quarter in the previous year, the firm earned ($1.38) EPS. As a group, equities research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of the business's stock in a transaction on Friday, September 12th. The shares were sold at an average price of $30.00, for a total transaction of $450,000.00. Following the completion of the sale, the insider owned 232,122 shares in the company, valued at approximately $6,963,660. The trade was a 6.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last three months, insiders have sold 40,000 shares of company stock worth $1,025,000. Insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.